444 related articles for article (PubMed ID: 27104893)
41. Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.
Pettigrew C; Soldan A; Moghekar A; Wang MC; Gross AL; O'Brien R; Albert M
Neuropsychologia; 2015 Nov; 78():63-72. PubMed ID: 26394023
[TBL] [Abstract][Full Text] [Related]
42. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
43. Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease.
Fonteh AN; Ormseth C; Chiang J; Cipolla M; Arakaki X; Harrington MG
PLoS One; 2015; 10(5):e0125597. PubMed ID: 25938590
[TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
45. Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology.
Negash S; Xie S; Davatzikos C; Clark CM; Trojanowski JQ; Shaw LM; Wolk DA; Arnold SE
Alzheimers Dement; 2013 May; 9(3):e89-95. PubMed ID: 23127468
[TBL] [Abstract][Full Text] [Related]
46. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
Schmand B; Eikelenboom P; van Gool WA;
J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
[TBL] [Abstract][Full Text] [Related]
47. Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease.
Ossenkoppele R; Lyoo CH; Jester-Broms J; Sudre CH; Cho H; Ryu YH; Choi JY; Smith R; Strandberg O; Palmqvist S; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; La Joie R; Rabinovici GD; Hansson O
JAMA Neurol; 2020 May; 77(5):632-642. PubMed ID: 32091549
[TBL] [Abstract][Full Text] [Related]
48. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
49. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
Schmand B; Eikelenboom P; van Gool WA;
J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
[TBL] [Abstract][Full Text] [Related]
50. Cognitive reserve and rate of change in Alzheimer's and cerebrovascular disease biomarkers among cognitively normal individuals.
Pettigrew C; Soldan A; Zhu Y; Cai Q; Wang MC; Moghekar A; Miller MI; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M
Neurobiol Aging; 2020 Apr; 88():33-41. PubMed ID: 31932050
[TBL] [Abstract][Full Text] [Related]
51. Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging.
Lee DH; Lee P; Seo SW; Roh JH; Oh M; Oh JS; Oh SJ; Kim JS; Jeong Y
Neuroimage; 2019 Feb; 186():690-702. PubMed ID: 30503934
[TBL] [Abstract][Full Text] [Related]
52. The EMIF-AD PreclinAD study: study design and baseline cohort overview.
Konijnenberg E; Carter SF; Ten Kate M; den Braber A; Tomassen J; Amadi C; Wesselman L; Nguyen HT; van de Kreeke JA; Yaqub M; Demuru M; Mulder SD; Hillebrand A; Bouwman FH; Teunissen CE; Serné EH; Moll AC; Verbraak FD; Hinz R; Pendleton N; Lammertsma AA; van Berckel BNM; Barkhof F; Boomsma DI; Scheltens P; Herholz K; Visser PJ
Alzheimers Res Ther; 2018 Aug; 10(1):75. PubMed ID: 30075734
[TBL] [Abstract][Full Text] [Related]
53. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.
Desikan RS; McEvoy LK; Thompson WK; Holland D; Brewer JB; Aisen PS; Sperling RA; Dale AM;
Arch Neurol; 2012 Jun; 69(6):709-13. PubMed ID: 22529247
[TBL] [Abstract][Full Text] [Related]
54. A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).
Niemantsverdriet E; Ribbens A; Bastin C; Benoit F; Bergmans B; Bier JC; Bladt R; Claes L; De Deyn PP; Deryck O; Hanseeuw B; Ivanoiu A; Lemper JC; Mormont E; Picard G; Salmon E; Segers K; Sieben A; Smeets D; Struyfs H; Thiery E; Tournoy J; Triau E; Vanbinst AM; Versijpt J; Bjerke M; Engelborghs S
J Alzheimers Dis; 2018; 63(4):1509-1522. PubMed ID: 29782314
[TBL] [Abstract][Full Text] [Related]
55. Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior.
Soldan A; Pettigrew C; Moghekar A; Albert M;
J Int Neuropsychol Soc; 2016 Nov; 22(10):968-977. PubMed ID: 27903332
[TBL] [Abstract][Full Text] [Related]
56. Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.
Poulin SP; Bergeron D; Dickerson BC;
J Alzheimers Dis; 2017; 60(2):483-493. PubMed ID: 28869463
[TBL] [Abstract][Full Text] [Related]
57. Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.
Babulal GM; Chen S; Williams MM; Trani JF; Bakhshi P; Chao GL; Stout SH; Fagan AM; Benzinger TLS; Holtzman DM; Morris JC; Roe CM
J Alzheimers Dis; 2018; 66(3):1213-1221. PubMed ID: 30400098
[TBL] [Abstract][Full Text] [Related]
58. Effect of cognitive reserve markers on Alzheimer pathologic progression.
Lo RY; Jagust WJ;
Alzheimer Dis Assoc Disord; 2013; 27(4):343-50. PubMed ID: 23552443
[TBL] [Abstract][Full Text] [Related]
59. Cognitive reserve predicts future executive function decline in older adults with Alzheimer's disease pathology but not age-associated pathology.
McKenzie C; Bucks RS; Weinborn M; Bourgeat P; Salvado O; Gavett BE;
Neurobiol Aging; 2020 Apr; 88():119-127. PubMed ID: 31980279
[TBL] [Abstract][Full Text] [Related]
60. Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease.
Archetti D; Ingala S; Venkatraghavan V; Wottschel V; Young AL; Bellio M; Bron EE; Klein S; Barkhof F; Alexander DC; Oxtoby NP; Frisoni GB; Redolfi A; ;
Neuroimage Clin; 2019; 24():101954. PubMed ID: 31362149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
